India: Supreme Court Expands Government's Powers To Ban Drugs Under Section 26a Of The Drugs & Cosmetics Act, 1940


On 10 March 2016, the Central Government issued 344 identically worded notifications (Notifications) prohibiting the manufacture, sale and distribution of 344 fixed dose combinations (FDCs). The Notifications purported to ban the FDCs in question because they posed substantial risks to human life and safer alternatives were available. The Notifications were purported to be based on the findings and recommendations of an expert committee appointed by the Central Government, which stated that the FDCs in question were found to have no 'therapeutic justification'. Lastly, the Notifications were touted as an exercise in 'public interest'. The Notifications were issued by the Central Government in exercise of its powers under Section 26A of the Drugs and Cosmetics Act, 1940 (Drugs Act). Five similar notifications were issued on 8 June 2017 whereby five FDCs were banned.

Challenge before the Delhi High Court

The pharmaceutical industry immediately proceeded to challenge the Notifications on various grounds. Although writ petitions were filed before various High Courts of the country, the Delhi High Court received over 500 petitions. The Delhi High Court accorded priority to these hotly contested matters and they were taken up for hearing on a day to day basis. In light of this, the Delhi High Court pronounced its judgment on 1 December 2016.

Judgment dated 1 December 2016

The Delhi High Court judgment came as a welcome relief to the pharmaceutical industry as all Notifications were set aside. Although several issues were raised, the Delhi High Court chose to answer the principal issue – whether consultation with Drugs Technical Advisory Board (DTAB) and Drugs Consultative Committee (DCC) is mandatory before exercise of powers by the Central Government under Section 26A of the Drugs Act. The Delhi High Court answered this issue in the affirmative and held that consultation with DTAB / DCC is sine qua non for exercise of powers under Section 26A of the Act.

Challenge before the Supreme Court

As the pharmaceutical industry expected, the Central Government challenged the judgment of the Delhi High Court before the Supreme Court. Although stay of the Delhi High Court judgment was not granted while issuing summons to the respondents (pharmaceutical companies), the Supreme Court appreciated the urgency and importance of these matters. Accordingly, it decided to do away with time taking procedures of issuing formal summons by the Supreme Court Registry and completion of pleadings which are prerequisites before which a matter can be finally heard by the Court. In the Supreme Court, the matters were heard by a bench comprising of Hon'ble Mr Justice R F Nariman and Hon'ble Mr Justice S K Kaul.

Supreme Court lays down the law

On 15 December 2017, the Supreme Court pronounced its judgment allowing the appeal of the Central Government.

The Supreme Court held that Section 26A does not mandate any previous consultation with the DTAB. On the contrary, the Central Government may be "satisfied" on any relevant material that a drug is likely to involve any risk to human life, as a result of which it is necessary in public interest to regulate, restrict or prohibit manufacture, sale or distribution thereof. So long as the Central Government is satisfaction, it can be said to be based on relevant material. However, the absence of any previous consultation with the DTAB, does not make the power exercised under Section 26A non-est.

Directions in respect of 344 FDCs

Despite setting aside the judgment of the Delhi High Court, the Supreme Court proceeded to refer the FDCs to DTAB so that it may examine each of these cases and ultimately send a report to the Central Government. However, the Supreme Court clarified that the considering peculiar facts of these cases and in order to obviate further litigation, the Court has sought the expertise of the DTAB for fresh examination of the FDCs. The Supreme Court further noted that the expert committee (Kokate Committee) did deliberate on the FDCs and come to a conclusion that the FDCs must be banned. However, the reasons for recommending a ban on the FDCs were not clear i.e., the exact reasons for such conclusions and whether it was necessary in the public interest to take the extreme step of prohibiting such FDCs, instead of restricting or regulating their manufacture and supply. Considering the same, the Supreme Court proceeded to set the parameters which are required to be met by DTAB for the re-examination of the use of the FDCs. The Supreme Court directed as under:

"33. First and foremost in each case, the DTAB/Sub-Committee appointed by it must satisfy itself that the use of the Fixed Dose Combinations (FDC) in question is likely to involve any one of the aforesaid three things:

(a) that they are likely to involve any risk to human beings or animals; or

(b) that the said FDCs do not have the therapeutic value claimed or purported to be claimed for them; or

(c) that such FDCs contain ingredients and in such quantity for which there is no therapeutic justification.

34. The DTAB/Sub-Committee must also apply its mind as to whether it is then necessary or expedient, in the larger public interest, to regulate, restrict or prohibit the manufacture, sale or distribution of such FDCs. In short, the DTAB/Sub-Committee must clearly indicate in its report:

(1) as to why, according to it, any one of the three factors indicated above is attracted;

(2) post such satisfaction, that in the larger public interest, it is necessary or expedient to (i) regulate, (ii) restrict, or (iii) prohibit the manufacture, sale or distribution of such FDCs.

35. The DTAB/Sub-Committee must also indicate in its report as to why, in case it prohibits a particular FDC, restriction or regulation is not sufficient to control the manufacture and use of the FDC. We request the DTAB/Sub-Committee to be set up for this purpose to afford the necessary hearing to all concerned, and thereafter submit a consolidated report, insofar as these FDCs are concerned, to the Central Government within a period of six months from the date on which this judgment is received by the DTAB. We may also indicate that the Central Government, thereafter, must have due regard to the report of the DTAB and to any other relevant information, and ultimately apply its mind to the parameters contained in Section 26A of the Drugs Act and, accordingly, either maintain the notifications already issued, or modify/substitute them or withdraw them."

It may be noted that certain drugs which were launched or first manufactured prior to 21 September 1988 have been excluded i.e., they have not been referred to DTAB. In respect of these drugs, the concerned Notifications have been set aside as those cases were never meant to be referred to the Kokate Committee. The Supreme Court did not agree with the pharmaceutical companies that the FDCs which are approved by DCG(I) should also be excluded for the reason that doubts have been raised by the Parliamentary Standing Committee in relation to the manner in which DCG(I) approvals had been granted.

The Supreme Court also granted interim protection in the form of status quo to the pharmaceuticals companies till such time a final decision is taken by the DTAB and the Central Government with respect to the FDCs.

In so far as the ban on 294 FDCs which were challenged before the Madras High Court in the year 2007, the Supreme Court noted that DTAB has already examined the 294 FDCs and has recommended prohibition on certain drugs. Hence, no direction has been passed in relation to the 294 FDCs but the Supreme Court accepted the report of DTAB.


The Hon'ble Supreme Court has expanded the powers of the Central Government under Section 26A of the Drugs Act thereby enabling the Central Government to prohibit the use and manufacture of any drug without the consultation of the DTAB or any other committee provided the parameters of Section 26A of the Drugs Act are met. Although the fate of the FDCs which have been referred to DTAB is still to be decided, the pharmaceutical companies can manufacture and sell those FDCs till the Central Government issues appropriate notifications after receiving the recommendation of DTAB. Also, the fate of pre 21 September 1988 FDCs which were approved by DCG(I) is not clear. One may argue that since these are launched pre 21 September 1988, they are outside the purview of the fresh exercise which DTAB has been directed to undertake. It can also be argued that since these are DCG(I) approved, DTAB is entitled to re-examine their safety and rationality. However, it may be noted that while pre 21 September 1988 FDCs have been excluded, the Supreme Court has preserved the right of the Central Government to carry out an inquiry as to whether such drugs should be the subject matter of a notification under Section 26A of the Drugs Act.

The content of this document do not necessarily reflect the views/position of Khaitan & Co but remain solely those of the author(s). For any further queries or follow up please contact Khaitan & Co at

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions